Sacituzumab govitecan: Additional Phase I/II data

Data from 60 evaluable patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) in the Phase II portion of an open-label Phase I/II trial showed that 10 mg/kg

Read the full 294 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE